Abstract
Adeno-associated viral vector (AAV)-mediated gene transfer represents a promising gene replacement strategy for treating Duchenne muscular dystrophy (DMD). However, recent studies demonstrated cellular immunity specific to AAV capsid proteins in animal models, which resulted in liver toxicity and elimination of transgene expression in a human trial of hemophilia B. We have recently developed immunosuppressive strategies to prevent such immunity for successful long-term transgene expression in dog muscle. Here, we describe in detail the immunosuppressive regimens employed in both normal and DMD dogs and provide methods for evaluating the efficiency of the regimens following intramuscular injection of AAV in dogs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Finsterer J, Stollberger C (2003) The heart in human dystrophinopathies Cardiol 99, 1–19.
Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes (Review). Lancet Neurol 2, 731–740.
Tyler KL (2003) Origins and early descriptions of “Duchenne muscular dystrophy”. Muscle Nerve 28, 402–422.
Foidart M, Foidart JM, Engel WK (1981) Collagen localization in normal and fibrotic human skeletal muscle. Arch Neurol 38, 152–157.
Duan D (2006) Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Genet 15 (Spec. No. 2), R253–R261.
Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, et al. (2006) rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12, 787–789.
Wang Z, Chamberlain JS, Tapscott SJ, Storb R (2009) Gene therapy in large animal models of muscular dystrophy. ILAR J 50, 187–198.
Athanasopoulos T, Fabb S, Dickson G (2000) Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases. Int J Mol Med 6, 363-375.
Sun B, Zhang H, Franco LM, Young SP, Schneider A, Bird A, et al. (2005) Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther 11, 57–65.
Yue Y, Ghosh A, Long C, Bostick B, Smith BF, Kornegay JN, et al. (2008) A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 16, 1944–1952.
Athanasopoulos T, Graham IR, Foster H, Dickson G (2004) Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 11 Suppl 1, S109–S121.
Warrington KH, Jr., Herzog RW (2006) Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 119, 571–603.
Wang Z, Allen JM, Riddell SR, Gregorevic P, Storb R, Tapscott SJ, et al. (2007) Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 18, 18–26.
Sabatino DE, Mingozzi F, Hui DJ, Chen H, Colosi P, Ertl HC, et al. (2005) Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol Ther 12, 1023–1033.
Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L, et al. (2006) Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 13, 77–87.
Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response (erratum appears in Nat Med 12, 592). Nat Med 12, 342-347.
Maris M, Storb R (2003) The transplantation of hematopoietic stem cells after non-myeloablative conditioning: A cellular therapeutic approach to hematologic and genetic diseases. Immunol Res 28, 13-24.
Kirk AD (2003) Crossing the bridge: large animal models in translational transplantation research. Immunol Rev 196, 176–196.
Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, et al. (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89, 3048–3054.
Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, et al. (1998) Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91, 2581–2587.
McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97, 3390–3400.
Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, et al. (2003) HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102, 2021–2030.
Storb R, Floersheim GL, Weiden PL, Graham TC, Kolb H-J, Lerner KG, et al. (1974) Effect of prior blood transfusions on marrow grafts: Abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 112, 1508–1516.
Buckley JD, Chard RL, Baehner RL, Nesbit ME, Lampkin BC, Woods WG, et al. (1989) Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group. Cancer 63, 1457–1465.
Storb R, Kolb HJ, Graham TC, Kolb H, Weiden PL, Thomas ED (1973) Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone. Blood 42, 601–609.
Storb R, Gluckman E, Thomas ED, Buckner CD, Clift RA, Fefer A, et al. (1974) Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 44, 57–75.
Doney K, Leisenring W, Storb R, Appelbaum FR, for the Seattle Bone Marrow Transplant Team (1997) Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med 126, 107–115.
Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS, et al. (2007) Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 15, 1160–1166.
Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, et al. (1995) Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 4, 1251–1258.
Acknowledgements
We thank Dr. Jeffery Chamberlain for providing vectors used in the protocols and Dr. Kathy High for providing the c-FIX plasmid. We thank E. Zellmer, Diana Jensen, Jenee O’Brian, and E. Finn for technical assistance, and A. Joslyn, B. Steinmetz, and their teams, and M. Spector, DVM, and J Duncan, DVM, for their care of the dogs. We further thank S. Carbonneau, H. Crawford, B. Larson, K. Carbonneau, Vermeulen, and D. Gayle for administrative assistance and manuscript preparation. This work was supported by NIH U54-HD47175 and the Seattle Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, NIH CA15704, NIH AR056949, and by Career Development Award for Z. Wang from the Muscular Dystrophy Association (MDA 114979).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Wang, Z., Tapscott, S.J., Storb, R. (2011). Local Gene Delivery and Methods to Control Immune Responses in Muscles of Normal and Dystrophic Dogs. In: Duan, D. (eds) Muscle Gene Therapy. Methods in Molecular Biology, vol 709. Humana Press. https://doi.org/10.1007/978-1-61737-982-6_17
Download citation
DOI: https://doi.org/10.1007/978-1-61737-982-6_17
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61737-981-9
Online ISBN: 978-1-61737-982-6
eBook Packages: Springer Protocols